Will FDA's nod for Millennium's subQ Velcade be a thorn in Onyx's side?
This article was originally published in Scrip
Executive Summary
With the US FDA's approval on 23 January of Millennium’s Velcade (bortezomib) for use as a subcutaneously administered drug, patients not only get more convenience and similar efficacy benefits against multiple myeloma and mantle-cell lymphoma as that demonstrated with the intravenous version of the drug, which has been on the US market for nearly a decade, but the new route of administration has been shown to have fewer adverse effects, said CEO Dr Deborah Dunsire.